Mr. Marc Corrado

• 
  www.synageva.com/Management.aspx - [Cached Version]
  Published on: 9/29/2008    Last Visited: 9/29/2008  

  Marc Corrado - Chief Business Officer
  ...
  Marc Corrado
  
  Chief Business Officer
  
  Marc Corrado joined Synageva in January 2008 as Chief Business Officer.Prior to joining Synageva, he held various positions of increasing responsibility in Global Business Development, Global Marketing and Mergers & Acquisitions at Rhône-Poulenc Rorer in Paris, France, and at Aventis in Bridgewater, New Jersey.In 2005, following Aventis' merger with Sanofi, Mr. Corrado became a corporate officer and VP, Corporate Development of EntreMed, a publicly-traded biotechnology company based in Rockville, Maryland.Mr. Corrado earned his J.D. degree from the American University in Washington, D.C., and his M.B.A. from INSEAD in Fontainebleau, France.
  
  Back To Top

• 
  www.sec.gov/Archives/edgar/data/895051/0000950133-07-00 - [Cached Version]
  Published on: 4/27/2007    Last Visited: 4/28/2007  

  Marc G. Corrado,

• 
  www.sec.gov/Archives/edgar/data/1318049/0001209191-06-0 - [Cached Version]
  Published on: 12/18/2006    Last Visited: 2/17/2007  

  0001318049 Corrado Marc C/O ENTREMED, INC. 9640 MEDICAL CENTER DRIVE ROCKVILLE MD 20850 0 1 0 0 VP Corporate Development

• 
  cincinnati.bizjournals.com/washington/stories/2007/11/2 - [Cached Version]
  Published on: 11/26/2007    Last Visited: 11/27/2007  

  Marc Corrado, one of six of the Rockville-based biotech company's management team, is leaving Dec. 17 to "accept other employment," according to a filing with the Securities and Exchange Commission.
  
  Corrado, who joined Entremed in March 2005, worked on attracting new business to help the company cut its losses.
  
  The company said Nov. 6 it lost $3 million, or 4 cents per share, compared to $3.5 million, or 5 cents per share in the same quarter a year ago.Third-quarter revenue was $3.52 million compared with $3.02 million in the year-ago quarter.
  
  Entremed also said it has enough money in the bank to fund operations into 2009.
  
  Corrado has not been replaced yet, according to the company's spokeswoman Ginny Dunn.
  ...
  Before joining Entremed, Corrado oversaw business development, global marketing and mergers and acquisitions for Aventis in Bridgewater, N.J., and Rhône-Poulenc Rorer in Paris before it merged with Hoechst in 2000.

• 
  investor.entremed.com/go.cfm?do=Page.View&id=180 - [Cached Version]
  Published on: 11/21/2005    Last Visited: 11/21/2005  

  Marc Corrado
  
  Board of Directors
  ...
  Marc Corrado Board of Directors Recent Company Presentation
  ...
  Marc Corrado
  ...
  Marc Corrado
  
  Vice President, Corporate Development
  
  Marc Corrado joined EntreMed in March 2005 as Vice President, Corporate Development.Prior to EntreMed, Marc held various positions of increasing responsibility in business development, global marketing and mergers & acquisitions at Rhône-Poulenc Rorer in Paris, France, and at Aventis in Bridgewater, New Jersey.Aventis, a $20 billion pharmaceutical company, merged with Sanofi in 2004 to form Sanofi-Aventis.
  
  In 1995, Marc joined Rhône-Poulenc Rorer in Paris, where he held various positions of increasing responsibility in Worldwide Business Development and Licensing.Specifically, he was responsible for identifying, evaluating and negotiating licensing opportunities, and for ensuring the success of co-development and co-commercialization collaborations.
  
  In 2000, following the merger between Rhône-Poulenc and Hoechst, Marc moved to Bridgewater as Director, Global Business Development at Aventis.While at Aventis, he became Director, Oncology New Product Commercialization within Global Marketing, and most recently Senior Director, Mergers & Acquisitions within Corporate Development.
  
  Marc holds a J.D. from the American University in Washington, D.C., and a M.B.A. from INSEAD in Fontainebleau, France.

• 
  www.sec.gov/Archives/edgar/data/1318049/000131804905000 - [Cached Version]
  Published on: 2/16/2005    Last Visited: 2/22/2005  

  0001318049 Corrado Marc 9640 MEDICAL CENTER DRIVE ROCKVILLE MD 20850 0 1 0 0 V.P. Corporate Development

• 
  www.dddmag.com/ShowPR.aspx?PUBCODE=016&ACCT=1600000100& - [Cached Version]
  Published on: 9/21/2007    Last Visited: 9/21/2007  

  Contributing Editor Ted Agres discussed company strategy with James S. Burns, president and CEO; Carolyn Sidor, MD, MBA, vice president and chief medical officer; and Marc Corrado, vice president for corporate development, at EntreMed's corporate offices in Rockville, Md.
  ...
  Corrado: From the outside, you might perceive it as a risky endeavor.
  ...
  Corrado: It's a little premature to give guidance on the responsibilities of parties in any collaboration.ENMD-981693 has shown indications of potential in a variety of tumor types.

• 
  www.entremed.com/news/entremed-to-present-at-canaccord- - [Cached Version]
  Published on: 8/7/2007    Last Visited: 12/11/2007  

  ROCKVILLE, MD - August 7, 2007 - EntreMed, Inc. (Nasdaq: ENMD) a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced today that Mr. Marc Corrado, Vice President, Corporate Development, will present a Company overview at the Canaccord Adams 27th Annual Global Growth Conference, which is being held August 7-9, 2007 in Boston.Mr. Corrado's presentation is scheduled for today at 3:30 p.m. (local time).
  
  Mr. Corrado's presentation will not be web cast; however, a copy of his presentation will be available through the Company's web site at www.entremed.com.

• 
  www.lead411.com/executives.taf?_function=alpharequest&l - [Cached Version]
  Published on: 5/13/2008    Last Visited: 5/13/2008  

  Marc Corrado

• 
  www.masshightech.com/stories/2008/09/08/weekly4-Synagev - [Cached Version]
  Published on: 8/25/2008    Last Visited: 9/15/2008  

  A large investor community, talented executives and a cluster of potential licensing partners were the biggest factors in coming to Boston, said Marc Corrado, the company's chief business officer.
  
  For now, the company's R&D and manufacturing facility will remain in Atlanta, he said.
  
  Synageva is focused on new oncology and autoimmune treatments using monoclonal antibodies and cytokines-based drugs.

Page:  1 2 3